Goldman Sachs’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.54B Buy
11,065,214
+2,312,701
+26% +$324M 0.18% 93
2025
Q4
$1.07B Buy
8,752,513
+1,630,711
+23% +$198M 0.13% 125
2025
Q3
$791M Buy
7,121,802
+879,442
+14% +$100M 0.1% 184
2025
Q2
$692M Sell
6,242,360
-543,837
-8% -$57.9M 0.09% 199
2025
Q1
$760M Sell
6,786,197
-662,554
-9% -$68.4M 0.12% 150
2024
Q4
$688M Buy
7,448,751
+305,163
+4% +$27.5M 0.11% 164
2024
Q3
$599M Sell
7,143,588
-2,036,226
-22% -$155M 0.1% 201
2024
Q2
$630M Buy
9,179,814
+3,989,275
+77% +$266M 0.11% 184
2024
Q1
$380M Sell
5,190,539
-4,451,078
-46% -$342M 0.07% 297
2023
Q4
$781M Sell
9,641,617
-1,456,702
-13% -$113M 0.14% 133
2023
Q3
$832M Buy
11,098,319
+466,416
+4% +$35.9M 0.18% 105
2023
Q2
$819M Buy
10,631,903
+144,579
+1% +$11.5M 0.18% 99
2023
Q1
$870M Buy
10,487,324
+1,120,063
+12% +$92.8M 0.2% 84
2022
Q4
$804M Buy
9,367,261
+1,404,678
+18% +$111M 0.2% 89
2022
Q3
$491M Sell
7,962,583
-582,779
-7% -$36.7M 0.12% 135
2022
Q2
$528M Buy
8,545,362
+1,242,886
+17% +$77M 0.13% 122
2022
Q1
$434M Buy
7,302,476
+533,202
+8% +$34.1M 0.09% 196
2021
Q4
$492M Sell
6,769,274
-801,385
-11% -$55.2M 0.1% 190
2021
Q3
$529M Sell
7,570,659
-1,352,373
-15% -$95M 0.11% 162
2021
Q2
$614M Buy
8,923,032
+5,648,535
+173% +$377M 0.14% 128
2021
Q1
$212M Buy
3,274,497
+571,826
+21% +$36.9M 0.05% 352
2020
Q4
$157M Sell
2,702,671
-592,916
-18% -$35.8M 0.04% 413
2020
Q3
$208M Sell
3,295,587
-3,891,824
-54% -$270M 0.06% 320
2020
Q2
$553M Sell
7,187,411
-1,152,131
-14% -$88.3M 0.17% 103
2020
Q1
$623M Sell
8,339,542
-3,595,076
-30% -$248M 0.22% 82
2019
Q4
$776M Buy
11,934,618
+2,103,489
+21% +$137M 0.2% 90
2019
Q3
$623M Sell
9,831,129
-273,073
-3% -$17.9M 0.18% 92
2019
Q2
$683M Buy
10,104,202
+391,040
+4% +$25.7M 0.2% 86
2019
Q1
$631M Buy
9,713,162
+570,724
+6% +$37.9M 0.19% 92
2018
Q4
$572M Sell
9,142,438
-606,828
-6% -$42.4M 0.18% 87
2018
Q3
$753M Buy
9,749,266
+410,922
+4% +$31M 0.19% 83
2018
Q2
$662M Sell
9,338,344
-3,445,174
-27% -$243M 0.18% 89
2018
Q1
$964M Buy
12,783,518
+647,647
+5% +$51.5M 0.25% 65
2017
Q4
$869M Buy
12,135,871
+870,571
+8% +$66.1M 0.21% 68
2017
Q3
$913M Buy
11,265,300
+1,417,106
+14% +$108M 0.22% 61
2017
Q2
$697M Buy
9,848,194
+794,271
+9% +$52.9M 0.18% 84
2017
Q1
$615M Buy
9,053,923
+1,373,263
+18% +$96.6M 0.17% 99
2016
Q4
$550M Buy
7,680,660
+2,222,718
+41% +$165M 0.16% 103
2016
Q3
$432M Sell
5,457,942
-3,564,487
-40% -$290M 0.13% 128
2016
Q2
$753M Buy
9,022,429
+2,237,867
+33% +$199M 0.25% 50
2016
Q1
$623M Sell
6,784,562
-2,498,928
-27% -$225M 0.2% 72
2015
Q4
$939M Buy
9,283,490
+477,535
+5% +$49.7M 0.29% 40
2015
Q3
$865M Sell
8,805,955
-1,018,093
-10% -$113M 0.29% 41
2015
Q2
$1.15B Sell
9,824,048
-9,739,392
-50% -$1.06B 0.36% 30
2015
Q1
$1.92B Sell
19,563,440
-13,599
-0.1% -$1.38M 0.62% 10
2014
Q4
$1.85B Buy
19,577,039
+3,142,434
+19% +$325M 0.58% 11
2014
Q3
$1.75B Sell
16,434,605
-11,914,429
-42% -$1.17B 0.56% 13
2014
Q2
$2.35B Buy
28,349,034
+7,972,186
+39% +$621M 0.74% 7
2014
Q1
$1.44B Buy
20,376,848
+7,277,458
+56% +$571M 0.47% 19
2013
Q4
$984M Buy
13,099,390
+2,739,818
+26% +$191M 0.32% 37
2013
Q3
$651M Buy
10,359,572
+2,567,407
+33% +$153M 0.24% 61
2013
Q2
$400M Buy
+7,792,165
New +$406M 0.15% 116

Other funds holding GILD

Goldman Sachs's GILD Position: Q1 2026 in Review

Goldman Sachs increased its Gilead Sciences (GILD) stake by 26% in Q1 2026, buying an estimated $324M and bringing the position to 11,065,214 shares worth $1.54B. The position accounts for 0.18% of the portfolio, ranked #93.

Goldman Sachs first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.35B in Q2 2014. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Goldman Sachs held 11,065,214 shares of Gilead Sciences worth $1.54B as of Q1 2026.
  • Goldman Sachs bought 2,312,701 Gilead Sciences shares in Q1 2026, an estimated $324M.
  • Gilead Sciences made up 0.18% of Goldman Sachs's portfolio in Q1 2026, its #93 holding.
  • Goldman Sachs first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Gilead Sciences position peaked at $2.35B in Q2 2014.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.